Overview

Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome

Status:
Unknown status

Trial end date:
2018-01-01

Target enrollment:
0

Participant gender:
Female

Summary

Project summary: Objective: To test the hypothesis that administration of vaginal Misoprostol before elective cesarean section will improve the neonatal respiratory outcomes in late preterm and early term neonates through induction of catecholamine surge. Design: Randomized controlled clinical trial. Setting: Women health center ,Assiut university hospital. Patients: mothers planned for cesarean section at 34 - 37weeks. Intervention: two hundred and ninety two women will be randomly allocated to receive either 50 micrograms of Misoprostol per vagina within one hour before cesarean section (study group; n= 146) or receive nothing (control group; n = 146) . Main outcome measure: Apgar score at 1 and 5 minutes.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Alprostadil
Misoprostol

Criteria

Inclusion Criteria:

All pregnant women who are planned for elective (planned& pre labor) cesarean section at 34
-37 weeks gestation.

Exclusion Criteria:

1. Pregnancies with known fetal malformation/s or chromosomal aberrations.

2. Presence of absolute contraindication for use of misoprostol.(i.e known
hypersensitivity to the drug)

3. Women before 34 and after 37 weeks gestation .

4. Non reassuring cardiotocogram immediately before recruitment.

5. multiple pregnancies.